LOW-DOSE CYTARABINE AND VENETOCLAX PLUS AZACITIDINE COMPARED WITH VENETOCLAX PLUS AZACITIDINE IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A MULTICENTER RANDOMIZED PHASE III TRIAL

EHA Library, Xiao Han, 4206679

OPTI-AML: PROSPECTIVE RANDOMIZED PHASE 2 TRIAL OF 28 VERSUS 14 DAY SCHEDULE OF VENETOCLAX AND AZACITIDINE FOR 2 CYCLES IN NEWLY DIAGNOSED GENOMICALLY AGNOSTIC ACUTE MYELOID LEUKEMIA PATIENTS ≥60 YEARS

EHA Library, Uma Borate, 4206680

A MULTICENTER PHASE 1B/2 TRIAL OF AZACITIDINE, VENETOCLAX, AND IVOSIDENIB IN IDH1-MUTATED ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Jennifer Marvin-Peek, 4206681

PROSPECTIVE NAMLG LD-VENEX TRIAL: AZACITIDINE IN COMBINATION WITH REDUCED DURATION OF VENETOCLAX IN PATIENTS WITH DE NOVO, SECONDARY, AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Anne Louise Tølbøll Sørensen, 4206683

TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND MINIMAL RESIDUAL DISEASE AT THE END OF FRONTLINE CONSOLIDATION

EHA Library, Shannon Maude, 4206689

IMPACT OF TWO VERSUS THREE CHEMOTHERAPY CYCLES BEFORE HSCT IN MRD-NEGATIVE PEDIATRIC AML: A MULTICENTER RETROSPECTIVE STUDY

EHA Library, Lindsey Murphy, 4206690

ANTHRACYCLINES-FREE TREATMENT OF 114 CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA (APL): EARLY FINAL RESULTS OF THE ICC-APL-02 STUDY.

EHA Library, Franco Locatelli, 4206691

EZH2 INACTIVATION AND HOXA9-MEDIATED REPROGRAMMING DRIVE HUMAN T-CELL LEUKEMOGENESIS AND DEFINE HIGH-RISK EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ETP-ALL)

EHA Library, Vincenzo Giambra, 4206693

CLONAL TRAJECTORIES OF CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTER TRANSFORMATION OVER THE PATIENTS’ LIFESPAN

EHA Library, Ian Márquez-López, 4206694

RESOLVING THE TUMOR HETEROGENEITY OF CLL SUBSET #8 AT SINGLE-CELL RESOLUTION: INSIGHTS INTO CLONAL DYNAMICS AND DISTINCT SUB-CLONAL MUTATIONAL LANDSCAPES

EHA Library, Athanasios Roussos, 4206696

PROSPECTIVE VALIDATION OF THE CLL-TIM MACHINE-LEARNING ALGORITHM PREDICTING INFECTION AND TREATMENT IN CLL: RESULTS FROM THE PHASE 2 CLINICAL TRIAL PREVENT-ACALL, NON-RANDOMIZED COHORT

EHA Library, Carsten Utoft Niemann, 4206697

A RIBOCANCER CELL LINE PANEL REVEALS THAT CLL-ASSOCIATED RPS15 MUTATIONS TRANSLATIONALLY REWIRE TRANSCRIPTION THROUGH CODON-SPECIFIC TRNA ACCOMMODATION DEFECTS

EHA Library, Marino Caruso, 4206698

ASC4FIRST WK 144 ANALYSIS: CONTINUED SUPERIOR EFFICACY AND FAVORABLE SAFETY OF ASCIMINIB VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA

EHA Library, Tim Hughes, 4206714

PONATINIB CONSOLIDATION AND DISCONTINUATION IN CML PATIENTS AFTER FAILED FIRST TFR ATTEMPT: UPDATED TFR OUTCOMES AND CHIP MUTATION ANALYSIS FROM THE RESTOP TRIAL

EHA Library, Gonzalo CARRENO, 4206715

HIGH RATES OF SUCCESSFUL SECOND STOP ATTEMPTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: RESULTS OF THE NAUT TRIAL

EHA Library, Katharina Kohlbrenner, 4206716

EFFICACY AND SAFETY OF ADDING LOW DOSE TYROSINE KINASE INHIBITORS (TKIS) FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO DO NOT ACHIEVE OPTIMAL RESPONSE OR A DEEP MOLECULAR REMISSION (ALERT CML)

EHA Library, Jay Yang, 4206717

ENABLE: UPDATED EFFICACY AND SAFETY RESULTS OF ELVN-001, A NOVEL SELECTIVE ATP-COMPETITIVE INHIBITOR OF BCR::ABL1, IN PATIENTS WITH PREVIOUSLY TREATED CP-CML

EHA Library, Dennis Kim, 4206718

CLONAL ARCHITECTURE AND DYNAMICS OF SOMATIC EVOLUTION IN APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Kudzai Nyamondo, 4206729

IN VIVO LENTIVIRAL GENE TRANSFER INTO HEMATOPOIETIC STEM CELLS FOR THE TREATMENT OF FANCONI ANEMIA

EHA Library, Michela Milani, 4206730

LONG-TERM OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY SEVERE APLASTIC ANEMIA

EHA Library, Fieke Hoff, 4206732

EARLY BONE FRAGILITY IS ASSOCIATED WITH VASCULAR ABNORMALITIES IN TELOMERE BIOLOGY DISORDERS: FINDINGS FROM THE MULTICENTER, INTERNATIONAL INSIGHT STUDY

EHA Library, Jane Koo, 4206733

SUCCESSFUL IN VIVO CAR-T GENERATION AND MINIMAL RESIDUAL DISEASE (MRD) CLEARANCE WITH KLN-1010 ACROSS DIVERSE BASELINE T CELL PHENOTYPES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Andrew Spencer, 4206739

THE DYNAMIC LANDSCAPE OF IMMUNE ENVIRONMENT FOR MM PATIENTS RECEIVING T CELL REDIRECTING THERAPIES

EHA Library, Haimeng Li, 4206740

AZD0120, A DUAL BCMA/CD19 CAR-T CELL THERAPY, DEMONSTRATES A NAIVE/CENTRAL MEMORY PHENOTYPE AND INDUCES A RAPID DECLINE IN SOLUBLE BCMA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Binod Dhakal, 4206741

DEVELOPMENT OF BMS-986453, A DUAL-TARGETING BCMA×GPRC5D CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Doris Hansen, 4206742

BTL-101, A FULLY HUMAN TRISPECIFIC BCMA×GPRC5D×CD3 T-CELL ENGAGER FOR THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Jiansong Yang, 4206743

MOSUNETUZUMAB FOR EARLY RELAPSE OF FOLLICULAR LYMPHOMA IN THE NORDIC COUNTRIES (MERLIN, NLG-FL6/ML43841)

EHA Library, Marianne Brodtkorb, 4206779

SAFETY AND EFFICACY OF SUBCUTANEOUS MOSUNETUZUMAB PLUS LENALIDOMIDE INDUCTION THERAPY FOLLOWED BY MOSUNETUZUMAB MAINTENANCE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

EHA Library, Emmanuel Bachy, 4206780

GOLCADOMIDE (GOLCA), A POTENTIAL, FIRST-IN-CLASS, ORAL CELMOD ±RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE (PH) 1/2 STUDY LONG-TERM FOLLOW-UP (F/U)

EHA Library, Daniel Morillo, 4206781

SUROVATAMIG (AZD0486) PLUS RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL): INITIAL SAFETY DATA FROM THE PHASE 3 SOUNDTRACK-F1 TRIAL

EHA Library, Chan Y. Cheah, 4206782

CLINICALLY RELEVANT SUBGROUP ANALYSIS FROM THE RANDOMIZED PHASE 3 EPCORE FL-1 TRIAL: TREATMENT (TX) EFFECT OF EPCORITAMAB WITH LENALIDOMIDE AND RITUXIMAB (R²) IN R/R FOLLICULAR LYMPHOMA (FL)

EHA Library, Benoit Tessoulin, 4206783

VT-EBV-N AS POST-REMISSION THERAPY SIGNIFICANTLY IMPROVES DISEASE-FREE SURVIVAL IN EBV-POSITIVE EXTRANODAL NK/T-CELL LYMPHOMA: A RANDOMIZED, DOUBLE-BLIND PHASE 2 TRIAL

EHA Library, Deok-Hwan Yang, 4206799

A PHASE I STUDY OF AUTOLOGOUS DUAL-EPITOPE NANOBODY-BASED ANTI-CD5 CAR T CELLS IN RELAPSED/REFRACTORY T-ALL/LBL AND PTCL/CTCL

EHA Library, Ming-Kun Wang, 4206800

HIGH-DOSE METHOTREXATE DOES NOT REDUCE RISK OF CNS RELAPSE IN ULTRA HIGH-RISK LARGE B-CELL LYMPHOMA: AN INTERNATIONAL RETROSPECTIVE ANALYSIS OF 1,923 PATIENTS

EHA Library, Matthew R. Wilson, 4206803

DEVELOPMENT AND VALIDATION OF THE FAC-HCT SCALE (FRAILTY, AGE AND COMORBIDITY) TO PREDICT OVERALL SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Maria Queralt Salas, 4206819

ABC: AN ENTIRELY CALCINEURIN AND M-TOR INHIBITOR-FREE SHORT DURATION GVHD PREVENTION REGIMEN

EHA Library, A Samer Al-Homsi, 4206820

FBEM (FLUDARABINE, BUSULFAN, ETOPOSIDE, AND MELPHALAN) CONDITIONING REGIMEN FOR PATIENTS WITH LYMPHOID MALIGNANCIES UNDERGOING ALLO-HSCT: A PROSPECTIVE PHASE II STUDY

EHA Library, Mengmeng Pan, 4206821

POST-TRANSPLANT MOLECULAR SURVEILLANCE REVEALS DIVERGENT CLINICAL TRAJECTORIES OF DONOR-DERIVED CLONAL HEMATOPOIESIS

EHA Library, Todd Knepper, 4206822

DONOR AGE DOES NOT AFFECT OUTCOMES OF HAPLOIDENTICAL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES: A STUDY BASED ON THE CHINESE BONE MARROW TRANSPLANTATION REGISTRY GROUP (CBMTRG)

EHA Library, Xuechun Wang, 4206823

ULTRA-SENSITIVE METABOLOMICS UNCOVERS L-CARNITINE AS A CRITICAL REGULATOR OF HUMAN HEMATOPOIETIC STEM CELL REGENERATION

EHA Library, Honglin Duan, 4206829

A TIME-RESOLVED SINGLE‑NUCLEUS MULTIOME ATLAS OF HUMAN FETAL LIVER HEMATOPOIESIS

EHA Library, Yiwei Niu, 4206830

THE LANDSCAPE OF SOMATIC RETROTRANSPOSON MUTATIONS IN HSCS, AND A NOVEL JAK2 SIGNALLING PATHWAY TO HNRNPA1 THAT REPRESSES RETROTRANSPOSON ACTIVITY

EHA Library, Stephen Loughran, 4206831

MITOCHONDRIAL DNA MOSAICISM AND CLONALITY IN HUMAN HEMATOPOIETIC AGING AND REGENERATION

EHA Library, Ambre Giguelay, 4206832

NIPOCALIMAB FOR WARM AUTOIMMUNE HEMOLYTIC ANEMIA: RESULTS FROM THE PHASE 2/3 RANDOMIZED DOUBLE-BLIND ENERGY STUDY

EHA Library, Bruno Fattizzo, 4206854

VENGLUSTAT DEMONSTRATES SUPERIOR NEUROLOGIC EFFICACY WHILE MAINTAINING SYSTEMIC CONTROL IN GAUCHER DISEASE TYPE 3: RESULTS FROM THE PHASE 3 LEAP2MONO TRIAL

EHA Library, Irene Motta, 4206857

EFFECTS OF MITAPIVAT ON IRON BURDEN AND SPLEEN SIZE IN ERYTHROCYTE MEMBRANOPATHIES AND CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II: 56-WEEK FOLLOW-UP RESULTS FROM THE SATISFY STUDY

EHA Library, Thomas Doeven, 4206858

OUTPATIENT TREATMENT WITH GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GEMOX) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): PRELIMINARY SAFETY RESULTS FROM A PHASE 2 STUDY

EHA Library, Dok Hyun Yoon, 4206889

REAL-WORLD EFFICACY AND SAFETY OF THE MEDZ-R REGIMEN AS INDUCTION THERAPY IN NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Liqun Zou, 4206890

PROSPECTIVE VALIDATION OF A WEIGHTED GAH SCORE IN PATIENTS ≥65 YEARS WITH LYMPHOPROLIFERATIVE NEOPLASMS: TOXICITY PREDICTION AND PROGNOSTIC IMPACT

EHA Library, Josefa Marco Buades, 4206894

TREATMENT ACCESS ELIMINATES RACIAL DISPARITIES BUT CANNOT OVERCOME STRUCTURAL POVERTY: A NATIONAL ANALYSIS OF SURVIVAL EQUITY IN CURABLE LYMPHOMA

EHA Library, Shivam Patel, 4206895

EPCORITAMAB + R-MINI-CHOP RESULTS IN 2-YEAR REMISSIONS AND HIGH MRD-NEGATIVITY RATES IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL: RESULTS FROM THE EPCORE NHL-2 TRIAL

EHA Library, David Belada, 4206896

ADDITION OF HIGH-DOSE METHOTREXATE TO STANDARD FIRST-LINE IMMUNOCHEMOTHERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IS ASSOCIATED WITH ACUTE BUT NOT CHRONIC KIDNEY DISEASE

EHA Library, Silje Post Strøm, 4206897

NOVA-BCL6-1: A FIRST-IN-HUMAN PHASE 1 TRIAL OF LY4584180, A NOVEL BCL6 MOLECULAR GLUE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (TRIAL IN PROGRESS)

EHA Library, Yair Levy, 4206898

EXTRANODAL METABOLIC TUMOR VOLUME IDENTIFIES LARGE B‑CELL LYMPHOMA SUBGROUPS THAT BENEFIT FROM POLA‑R‑CHP

EHA Library, Hajime Sakuma, 4206901

REAL-WORLD (RW) TREATMENT PATTERNS AND SURVIVAL OUTCOMES IN PATIENTS (PTS) WITH NEWLY DIAGNOSED HIGH-RISK (HR) LARGE B-CELL LYMPHOMA (LBCL)

EHA Library, Javier Munoz, 4206903

RECEIPT OF HOLDING THERAPY IS ASSOCIATED WITH INFERIOR OUTCOMES ACROSS THE CAR T TREATMENT PATHWAY IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA

EHA Library, Inna Gong, 4206904

THE CLINICAL SIGNIFICANCE OF MYC::BCL6 FUSION IN MYC/BCL6 DOUBLE HIT LYMPHOMA PATIENTS

EHA Library, Shaoying Li, 4206905

POLA-R-CHP VS R-EPOCH FOR FRONTLINE THERAPY IN DLBCL WITH EXTRANODAL INVOLVEMENT

EHA Library, Li Bao, 4206906

MULTIVARIABLE ANALYSES OF OVERALL SURVIVAL IN THE PHASE 3 SUNMO, STARGLO AND POLARGO TRIALS IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Matthew Matasar, 4206907

IMMUNE DEFICIENCY AND INFECTION RISK FOLLOWING  SECOND LINE CAR-T CELLS THERAPY IN RELAPSED REFRACTORY LARGE B CELLS LYMPHOMA

EHA Library, Mohamad Sabbah, 4206908

FLOW CYTOMETRY OF VITRECTOMY SAMPLES AS A DIAGNOSTIC TOOL IN PRIMARY VITREORETINAL LYMPHOMA

EHA Library, Lena-Marie Poczka, 4206909

OUTCOMES OF CONSOLIDATIVE RADIOTHERAPY AND SURVIVAL IN LIMITED-STAGE PRIMARY GASTRIC DIFFUSE LARGE B-CELL LYMPHOMA ACHIEVING COMPLETE RESPONSE: A MULTICENTER STUDY FROM CHINA

EHA Library, Natalia Sunarto, 4206910

INTERNATIONAL EXPERT CONSENSUS ON REAL-WORLD CAR T-CELL ELIGIBILITY IN LARGE B-CELL LYMPHOMAS: AN E-DELPHI STUDY

EHA Library, Catherine Thieblemont, 4206912

LARGE B-CELL LYMPHOMA TREATMENT WITH LONCASTUXIMAB TESIRINE IN AN ITALIAN REAL-LIFE EXPERIENCE

EHA Library, Alessandro Broccoli, 4206913

METAGENOMIC STUDY ON THE DYNAMIC CHANGES OF GUT MICROBIOME-METABOLOME IN DIFFUSE LARGE B-CELL LYMPHOMA: A COHORT ANALYSIS BASED ON PATIENTS' HEALTHY COHABITANTS AS CONTROL

EHA Library, Sai Huang, 4206914

EARLY TOXICITY OF AXICABTAGENE CILOLEUCEL BY LINE OF THERAPY IN DLBCL: A REAL-WORLD COMPARISON OF 2L VS ≥3L TREATMENT

EHA Library, Rebeca Bailen, 4206915

ZANUBRUTINIB PLUS R-CHOP (ZR-CHOP) IN NON-GERMINAL CENTER B-CELL-LIKE (NON-GCB) DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WHO WERE POSITRON EMISSION TOMOGRAPHY-POSITIVE AFTER TWO CYCLES OF R-CHOP

EHA Library, Jie Wang, 4206916

EFFICACY OF CAR-T CELL THERAPY IN DOUBLE-EXPRESSOR TP53-POSITIVE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTER REAL-WORLD STUDY

EHA Library, Shihui Ren, 4206917

OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH EPSTEIN-BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV+ PTLD) TREATED WITH TABELECLEUCEL IN THE PHASE 3 ALLELE TRIAL

EHA Library, Sylvain Choquet, 4206918

UPDATED CLINICAL DATA FROM THE PHASE 1/2 STUDY OF DIBOTATUG (DR-01), A NON-FUCOSYLATED ANTI-CD94 ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY CYTOTOXIC T/NK CELL LYMPHOMAS

EHA Library, Swaminathan Iyer, 4206919

PRELIMINARY EFFICACY AND SAFETY OF GOLIDOCITINIB IN RELAPSED/REFRACTORY T CELL AND NK CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA

EHA Library, Ying Yu, 4206920

SINGLE-CELL ANALYSES IDENTIFY A DISTINCT MYELOID CELL ECOSYSTEM ASSOCIATED WITH TREATMENT RESISTANCE IN ANAPLASTIC LARGE CELL LYMPHOMA

EHA Library, Putri Ramadani, 4206921

REAL-WORLD MANAGEMENT AND OUTCOMES OF PTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA: INSIGHTS FROM THE FRENCH REALYSA COHORT.

EHA Library, Loic Renaud, 4206923

THE REAL-WORLD EFFICACY OF BRUTON’S TYROSINE KINASE INHIBITORS PLUS HIGH-DOSE METHOTREXATE BASED INDUTION TREATMENT FOR UNTREATED PRIMARY CNS LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS.

EHA Library, He Huang, 4206924

THE AITL-HZ SCORE INCORPORATING EBV AND COMPLEMENT C3 OUTPERFORMS EXISTING PROGNOSTIC MODELS FOR CHINESE AITL PATIENTS

EHA Library, Mengmeng Dong, 4206926

BLOOD CANCER ASSOCIATED HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IS MORE LIKELY IN YOUNGER PATIENTS, AND ONLY AGE AND T-, NKT- AND NK-CELL LYMPHOMA DIAGNOSIS IMPACT SURVIVAL.

EHA Library, Mark Bishton, 4206927

COMPARABLE EFFICACY AND SAFETY OF BRENTUXIMAB VEDOTIN -BASED THERAPY TO THE ECHELON TRIALS: REAL-WORLD EVIDENCE FROM THE BRAVE STUDY

EHA Library, Mingci Cai, 4206928

MANAGEMENT AND OUTCOME OF SECONDARY CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN AN INTERNATIONAL COHORT OF 62 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)

EHA Library, Andrés José María Ferreri, 4206929

TABELECLEUCEL FOR ALLOGENEIC OR SOLID ORGAN TRANSPLANT RECIPIENTS WITH EBV+ PTLD AFTER FAILURE OF RITUXIMAB OR RITUXIMAB PLUS CHEMOTHERAPY: PAEDIATRIC SUBGROUP ANALYSIS OF THE PHASE 3 ALLELE STUDY

EHA Library, Pere Barba, 4206930

FINAL RESULTS OF THE PHASE II S-IDE STUDY: ADDING SELINEXOR TO IFOSFAMIDE, ETOPOSIDE, AND DEXAMETHASONE DID NOT IMPROVE OUTCOMES IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMAS

EHA Library, Annalisa Chiappella, 4206932

MOLECULAR LANDSCAPE OF PEDIATRIC B-CELL LYMPHOBLASTIC LYMPHOMA

EHA Library, Ekaterina Romanenko, 4206933

AN OPEN LABEL, PHASE 2 TRIAL EVALUATING DARATUMUMAB-BORTEZOMIB-DEXAMETHASONE COMBINATION IN RELAPSED OR REFRACTORY PLASMABLASTIC LYMPHOMA: THE DALYA TRIAL ON BEHALF OF THE FONDAZIONE ITALIANA LINFOMI

EHA Library, Andrés José María Ferreri, 4206934

FACILITY-LEVEL DIFFERENCES TRANSLATE INTO LIVES LOST: ELDERLY PRIMARY CNS LYMPHOMA IN THE NATIONAL CANCER DATABASE

EHA Library, Rosa Rios, 4206936

AMPLIFICATION OF STAT3 AND TP53 MAY CONFER POOR PROGNOSIS IN PERIPHERAL T-CELL LYMPHOMA: ANALYSIS OF A SINGLE-CENTER COHORT

EHA Library, Alessandro Putelli, 4206937

PROPOSED DEFINITION FOR ‘PRIMARY REFRACTORY’ DISEASE IN NODAL PERIPHERAL T-CELL LYMPHOMA: AN AUSTRALASIAN-CANADIAN COLLABORATIVE STUDY

EHA Library, John Kuruvilla, 4206939

BRENTUXIMAB VEDOTIN PLUS CHP-LIKE VERSUS CHOEP REGIMEN FOR THE FIRST-LINE TREATMENT OF PTCL PATIENTS: A MULTI-CENTER PROPENSITY-MATCHED POPULATION-BASED STUDY

EHA Library, Jun Fang, 4206940

RARE GERMLINE VARIANTS SHAPE SUSCEPTIBILITY AND PROGNOSIS IN B-CELL LYMPHOMAS

EHA Library, Weicheng Ren, 4206941

EFFICACY AND SAFETY OF GOLIDOCITINIB-CONTAINING REGIMENS IN RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA: A REAL WORLD STUDY

EHA Library, Liufang Gu, 4206942

PHASE IB STUDY OF SHR0302 PLUS SHR2554 IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA: SAFETY RUN-IN AND INITIAL EFFICACY

EHA Library, Rong Tao, 4206946

TARGETING TNFR2 WITH BI-1808 WITH OR WITHOUT PEMBROLIZUMAB: IMMUNE ACTIVATION AND PROMISING RESPONSES IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS

EHA Library, Stefan Barta, 4206947

CHANGES IN LEAN MUSCLE MASS, MUSCLE STRENGTH, AND PHYSICAL PERFORMANCE FOLLOWING FIRST‐LINE CHEMOTHERAPY IN PATIENTS WITH MALIGNANT LYMPHOMA

EHA Library, Charlotte Grønset, 4206948

TOTAL METABOLIC TUMOR VOLUME AND CIRCULATING TUMOR DNA AS EARLY PROGNOSTIC FACTORS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM THE PHASE 3 STARGLO TRIAL

EHA Library, William Townsend, 4206950

SPATIAL TRANSCRIPTOMICS REVEALS STEPWISE FORMATION OF DISTINCT CUTANEOUS NICHES IN NODAL T FOLLICULAR HELPER CELL LYMPHOMA

EHA Library, Yuri Tsuboi, 4206951

EARLY OUTCOME PREDICTION OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS USING ON-TREATMENT OMICS DATA

EHA Library, Tom van den Bosch, 4206952

PLASMA PROTEOMIC SIGNATURES DISTINGUISH LYMPHOMA FROM OTHER CANCERS AND NON-MALIGNANT CONDITIONS IN PATIENTS PRESENTING WITH NON-SPECIFIC SYMPTOMS

EHA Library, Fredrika Wannberg, 4206953

SPATIAL PROFILING OF T CELL SUBSETS REVEALS DISTINCT IMMUNE MICROENVIRONMENT PATTERNS ASSOCIATED WITH SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Filippa Wikström, 4206955

GENOMIC AND TRANSCRIPTOMIC LANDSCAPE OF FOLLICULAR LYMPHOMA

EHA Library, Matin Salehi, 4206956

INTEGRATION OF END-OF-TREATMENT CIRCULATING TUMOR DNA WITH PET-CT IMPROVES RESPONSE ASSESSMENT IN CLASSICAL HODGKIN LYMPHOMA

EHA Library, Vincent Camus, 4206957

REDUCED CD20 EXPRESSION AND INTRATUMORAL CD3+ T CELLS FOLLOWING EPCORITAMAB TREATMENT ARE ASSOCIATED WITH PROGRESSIVE DISEASE IN A SUBSET OF DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA

EHA Library, Monica Wielgos-Bonvallet, 4206958

OUTCOMES BY LYMPHOMAP ARCHETYPES IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL

EHA Library, R. Andrew Harkins, 4206959